Curriculum
Navigating GLP-1 RA Therapy to Improve Health Outcomes in Type 2 Diabetes: Practical Considerations for Primary Care
This curriculum includes a 60-minute virtual session and an interactive infographic activity. Through these activities, you will gain insights into the prompt treatment of T2DM, comparing available and emerging GLP-1 RAs for glycemic control, weight loss, and cardiovascular/renal benefits. You will also develop strategies to initiate GLP-1 RA therapy per guidelines, and address approaches to mitigate potential side effects, supporting a comprehensive treatment strategy for optimized patient outcomes.
CME Information
1.25 AMA PRA Category 1 Credits™, 1.25 ABIM MOC or 1.25 AANP, 1.25 AANP Pharm
Release Date: 11/1/2024
Available for credit until 11/1/2025
Topics
Learning Objectives
- Describe the importance of prompt and appropriate treatment to delay or prevent complications in people with T2D
- Differentiate between available and emerging GLP-1 RAs with reference to glycemic lowering efficacy, weight effects, and CV/renal benefits
- Initiate GLP-1 RA therapy in appropriate individuals according to guidelines, as part of a comprehensive treatment strategy
- Discuss and implement strategies for mitigating and treating potential side effects of GLP-1 RA therapy
Courses
1.25 CME/CE CREDITS
2 Courses
-
Virtual CME Program
-
Interactive Learning
Faculty
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor & Diabetologist, Department of Clinical Sciences & Community Health, Touro University California, Vallejo, CA
Cecilia C. Low Wang, MD, FACE, FACP
Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado